Suchergebnisse - "Satoh, Taroh"

PubPharm (472)

1

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers : NIR-B

enthalten in: Future oncology (London, England) | 2024

von Kawamoto, Y. | Morizane, C. | Komatsu, Y. | +14

2

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer : 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

enthalten in: Esophagus : official journal of the Japan Esophageal Society | 2024

von Kato, K. | Kojima, T. | Hara, H. | +13

3

Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma : subgroup analysis from RATIONALE-302

enthalten in: Esophagus : official journal of the Japan Esophageal Society | 2024

von Hara, H. | Satoh, T. | Kojima, T. | +9

4

Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer

enthalten in: Anticancer research | 2024

von Hara, S. | Sakai, D. | Ikemura, K. | +4

5

Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer : Results of the Japanese Expanded Access Program

enthalten in: Clinical colorectal cancer | 2024

von Kotani, D. | Takashima, A. | Kato, T. | +16

6

Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302

enthalten in: Esophagus | 2024

von Hara, H. | Satoh, T. | Kojima, T. | +9

7

Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer : Results From the GI-SCREEN CRC-Ukit Study

enthalten in: Clinical colorectal cancer | 2024

von Yuki, S. | Yamazaki, K. | Sunakawa, Y. | +18

8

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

enthalten in: International journal of clinical oncology | 2024

von Kawase, T. | Imamura, H. | Kawabata, R. | +11

9

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma : A Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Qin, S. | Kudo, M. | Meyer, T. | +13

10

Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer

enthalten in: International journal of clinical oncology | 2023

von Nishikawa, K. | Kawakami, H. | Shimokawa, T. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[48]